Company news

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) news

Terns Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 10, 2026: TERN Awarded $11.26 Million U.S. Army Contract to Deploy Next Generation Positioning…

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) news

Press releases & updates

TERN Awarded $11.26 Million U.S. Army Contract to Deploy Next Generation Positioning, Navigation, and Vehicle Readiness Systems

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Terns Pharmaceuticals Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4)

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Terns Announces Proposed Public Offering

Terns Announces Pricing of Upsized $650 Million Public Offering

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Terns Announces Pricing of Upsized $150.15 Million Public Offering

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates

Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition

Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation

Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day

Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates

Terns Pharmaceuticals Announces Leadership Changes

Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024

Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation

Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer